Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 283

1.

Amyloid-β, Tau, and 18F-Fluorodeoxyglucose Positron Emission Tomography in Posttraumatic Stress Disorder.

Elias A, Cummins T, Lamb F, Tyrrell R, Dore V, Williams R, Rosenfeld JV, Hopwood M, Villemagne VL, Rowe CC.

J Alzheimers Dis. 2019 Nov 18. doi: 10.3233/JAD-190913. [Epub ahead of print]

PMID:
31771068
2.

Clinical meaningfulness of subtle cognitive decline on longitudinal testing in preclinical AD.

Papp KV, Buckley R, Mormino E, Maruff P, Villemagne VL, Masters CL, Johnson KA, Rentz DM, Sperling RA, Amariglio RE; Collaborators from the Harvard Aging Brain Study, the Alzheimer's Disease Neuroimaging Initiative and the Australian Imaging, Biomarker and Lifestyle Study of Aging.

Alzheimers Dement. 2019 Nov 20. pii: S1552-5260(19)35446-9. doi: 10.1016/j.jalz.2019.09.074. [Epub ahead of print]

3.

Validation of a priori candidate Alzheimer's disease SNPs with brain amyloid-beta deposition.

Vacher M, Porter T, Villemagne VL, Milicic L, Peretti M, Fowler C, Martins R, Rainey-Smith S, Ames D, Masters CL, Rowe CC, Doecke JD, Laws SM.

Sci Rep. 2019 Nov 19;9(1):17069. doi: 10.1038/s41598-019-53604-5.

4.

Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.

Burnham SC, Coloma PM, Li QX, Collins S, Savage G, Laws S, Doecke J, Maruff P, Martins RN, Ames D, Rowe CC, Masters CL, Villemagne VL.

J Prev Alzheimers Dis. 2019;6(4):248-255. doi: 10.14283/jpad.2019.25.

PMID:
31686097
5.

Using subjective cognitive decline to identify high global amyloid in community-based samples: A cross-cohort study.

Buckley RF, Sikkes S, Villemagne VL, Mormino EC, Rabin JS, Burnham S, Papp KV, Doré V, Masters CL, Properzi MJ, Schultz AP, Johnson KA, Rentz DM, Sperling RA, Amariglio RE.

Alzheimers Dement (Amst). 2019 Sep 25;11:670-678. doi: 10.1016/j.dadm.2019.08.004. eCollection 2019 Dec.

6.

Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimer's disease.

Hadoux X, Hui F, Lim JKH, Masters CL, Pébay A, Chevalier S, Ha J, Loi S, Fowler CJ, Rowe C, Villemagne VL, Taylor EN, Fluke C, Soucy JP, Lesage F, Sylvestre JP, Rosa-Neto P, Mathotaarachchi S, Gauthier S, Nasreddine ZS, Arbour JD, Rhéaume MA, Beaulieu S, Dirani M, Nguyen CTO, Bui BV, Williamson R, Crowston JG, van Wijngaarden P.

Nat Commun. 2019 Sep 17;10(1):4227. doi: 10.1038/s41467-019-12242-1.

7.

The dawn of robust individualised risk models for dementia.

Burnham SC, Loi SM, Doecke J, Fedyashov V, Dore V, Villemagne VL, Masters CL.

Lancet Neurol. 2019 Nov;18(11):985-987. doi: 10.1016/S1474-4422(19)30353-9. Epub 2019 Sep 13. No abstract available.

PMID:
31526626
8.

A harmonized longitudinal biomarkers and cognition database for assessing the natural history of preclinical Alzheimer's disease from young adulthood and for designing prevention trials.

Xiong C, Luo J, Agboola F, Li Y, Albert M, Johnson SC, Koscik RL, Masters CL, Soldan A, Villemagne VL, Li QX, McDade EM, Fagan AM, Massoumzadeh P, Benzinger T, Hassenstab J, Bateman RJ, Morris JC; Dominantly Inherited Alzheimer Network.

Alzheimers Dement. 2019 Nov;15(11):1448-1457. doi: 10.1016/j.jalz.2019.06.4955. Epub 2019 Sep 7.

PMID:
31506247
9.

Visual paired associate learning deficits associated with elevated beta-amyloid in cognitively normal older adults.

Baker JE, Pietrzak RH, Laws SM, Ames D, Villemagne VL, Rowe CC, Masters CL, Maruff P, Lim YY.

Neuropsychology. 2019 Oct;33(7):964-974. doi: 10.1037/neu0000561. Epub 2019 Aug 1.

PMID:
31368758
10.

Effect of a 24-month physical activity program on brain changes in older adults at risk of Alzheimer's disease: the AIBL active trial.

Venkatraman VK, Sanderson A, Cox KL, Ellis KA, Steward C, Phal PM, Gorelik A, Sharman MJ, Villemagne VL, Lai M, Cyarto EV, Merkel B, Ames D, Szoeke C, Rowe CC, Masters CL, Lautenschlager NT, Desmond PM.

Neurobiol Aging. 2019 May 27. pii: S0197-4580(19)30155-1. doi: 10.1016/j.neurobiolaging.2019.02.030. [Epub ahead of print]

PMID:
31324405
11.

Four-repeat tauopathies.

Rösler TW, Tayaranian Marvian A, Brendel M, Nykänen NP, Höllerhage M, Schwarz SC, Hopfner F, Koeglsperger T, Respondek G, Schweyer K, Levin J, Villemagne VL, Barthel H, Sabri O, Müller U, Meissner WG, Kovacs GG, Höglinger GU.

Prog Neurobiol. 2019 Sep;180:101644. doi: 10.1016/j.pneurobio.2019.101644. Epub 2019 Jun 22. Review.

PMID:
31238088
12.

The trinity of tau, trauma, and time.

Villemagne VL, Doré V, Burnham S.

Lancet Neurol. 2019 Aug;18(8):715-717. doi: 10.1016/S1474-4422(19)30219-4. Epub 2019 Jun 11. No abstract available.

PMID:
31201004
13.

Increased cerebral blood flow with increased amyloid burden in the preclinical phase of alzheimer's disease.

Fazlollahi A, Calamante F, Liang X, Bourgeat P, Raniga P, Dore V, Fripp J, Ames D, Masters CL, Rowe CC, Connelly A, Villemagne VL, Salvado O; Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group.

J Magn Reson Imaging. 2019 May 30. doi: 10.1002/jmri.26810. [Epub ahead of print]

PMID:
31145515
14.

Comparison of 18F-florbetaben quantification results using the standard Centiloid, MR-based, and MR-less CapAIBL® approaches: Validation against histopathology.

Doré V, Bullich S, Rowe CC, Bourgeat P, Konate S, Sabri O, Stephens AW, Barthel H, Fripp J, Masters CL, Dinkelborg L, Salvado O, Villemagne VL, De Santi S.

Alzheimers Dement. 2019 Jun;15(6):807-816. doi: 10.1016/j.jalz.2019.02.005. Epub 2019 May 14.

PMID:
31101517
15.

COMT val158met is not associated with Aβ-amyloid and APOE ε4 related cognitive decline in cognitively normal older adults.

Porter T, Burnham SC, Milicic L, Savage G, Maruff P, Sohrabi HR, Peretti M, Lim YY, Weinborn M, Ames D, Masters CL, Martins RN, Rainey-Smith S, Rowe CC, Salvado O, Groth D, Verdile G, Villemagne VL, Laws SM.

IBRO Rep. 2019 May 2;6:147-152. doi: 10.1016/j.ibror.2019.05.001. eCollection 2019 Jun.

16.

Sensitivity of a Preclinical Alzheimer's Cognitive Composite (PACC) to amyloid β load in preclinical Alzheimer's disease.

Bransby L, Lim YY, Ames D, Fowler C, Roberston J, Harrington K, Snyder PJ, Villemagne VL, Salvado O, Masters CL, Maruff P for the AIBL Research Group.

J Clin Exp Neuropsychol. 2019 Aug;41(6):591-600. doi: 10.1080/13803395.2019.1593949. Epub 2019 Mar 29.

PMID:
30924399
17.

A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer's disease.

Ashton NJ, Nevado-Holgado AJ, Barber IS, Lynham S, Gupta V, Chatterjee P, Goozee K, Hone E, Pedrini S, Blennow K, Schöll M, Zetterberg H, Ellis KA, Bush AI, Rowe CC, Villemagne VL, Ames D, Masters CL, Aarsland D, Powell J, Lovestone S, Martins R, Hye A.

Sci Adv. 2019 Feb 6;5(2):eaau7220. doi: 10.1126/sciadv.aau7220. eCollection 2019 Feb.

18.

Klotho allele status is not associated with Aβ and APOE ε4-related cognitive decline in preclinical Alzheimer's disease.

Porter T, Burnham SC, Milicic L, Savage G, Maruff P, Lim YY, Ames D, Masters CL, Martins RN, Rainey-Smith S, Rowe CC, Salvado O, Groth D, Verdile G, Villemagne VL, Laws SM.

Neurobiol Aging. 2019 Apr;76:162-165. doi: 10.1016/j.neurobiolaging.2018.12.014. Epub 2019 Jan 6.

PMID:
30716541
19.

Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults.

Buckley RF, Mormino EC, Rabin JS, Hohman TJ, Landau S, Hanseeuw BJ, Jacobs HIL, Papp KV, Amariglio RE, Properzi MJ, Schultz AP, Kirn D, Scott MR, Hedden T, Farrell M, Price J, Chhatwal J, Rentz DM, Villemagne VL, Johnson KA, Sperling RA.

JAMA Neurol. 2019 May 1;76(5):542-551. doi: 10.1001/jamaneurol.2018.4693.

PMID:
30715078
20.

Imaging of tau deposits in adults with Niemann-Pick type C disease: a case-control study.

Villemagne VL, Velakoulis D, Doré V, Bozinoski S, Masters CL, Rowe CC, Walterfang M.

Eur J Nucl Med Mol Imaging. 2019 May;46(5):1132-1138. doi: 10.1007/s00259-019-4273-7. Epub 2019 Jan 28.

PMID:
30690666
21.

A Polygenic Risk Score Derived From Episodic Memory Weighted Genetic Variants Is Associated With Cognitive Decline in Preclinical Alzheimer's Disease.

Porter T, Burnham SC, Savage G, Lim YY, Maruff P, Milicic L, Peretti M, Ames D, Masters CL, Martins RN, Rainey-Smith S, Rowe CC, Salvado O, Taddei K, Groth D, Verdile G, Villemagne VL, Laws SM.

Front Aging Neurosci. 2018 Dec 19;10:423. doi: 10.3389/fnagi.2018.00423. eCollection 2018.

22.

Centiloid scaling for quantification of brain amyloid with [18F]flutemetamol using multiple processing methods.

Battle MR, Pillay LC, Lowe VJ, Knopman D, Kemp B, Rowe CC, Doré V, Villemagne VL, Buckley CJ.

EJNMMI Res. 2018 Dec 5;8(1):107. doi: 10.1186/s13550-018-0456-7.

23.

Diagnostic accuracy of imaging brain vesicular monoamine transporter type 2 (VMAT2) in clinically uncertain parkinsonian syndrome (CUPS): a 3-year follow-up study in community patients.

Xu SS, Alexander PK, Lie Y, Dore V, Bozinovski S, Mulligan RS, Young K, Villemagne VL, Rowe CC.

BMJ Open. 2018 Nov 15;8(11):e025533. doi: 10.1136/bmjopen-2018-025533.

24.

Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.

Porter T, Burnham SC, Milicic L, Savage G, Maruff P, Lim YY, Li QX, Ames D, Masters CL, Rainey-Smith S, Rowe CC, Salvado O, Groth D, Verdile G, Villemagne VL, Laws SM; AIBL Research Group.

J Alzheimers Dis. 2018;66(3):1193-1211. doi: 10.3233/JAD-180713.

PMID:
30412495
25.

Mediterranean diet adherence and rate of cerebral Aβ-amyloid accumulation: Data from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing.

Rainey-Smith SR, Gu Y, Gardener SL, Doecke JD, Villemagne VL, Brown BM, Taddei K, Laws SM, Sohrabi HR, Weinborn M, Ames D, Fowler C, Macaulay SL, Maruff P, Masters CL, Salvado O, Rowe CC, Scarmeas N, Martins RN.

Transl Psychiatry. 2018 Oct 30;8(1):238. doi: 10.1038/s41398-018-0293-5.

26.

Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology.

La Joie R, Ayakta N, Seeley WW, Borys E, Boxer AL, DeCarli C, Doré V, Grinberg LT, Huang E, Hwang JH, Ikonomovic MD, Jack C Jr, Jagust WJ, Jin LW, Klunk WE, Kofler J, Lesman-Segev OH, Lockhart SN, Lowe VJ, Masters CL, Mathis CA, McLean CL, Miller BL, Mungas D, O'Neil JP, Olichney JM, Parisi JE, Petersen RC, Rosen HJ, Rowe CC, Spina S, Vemuri P, Villemagne VL, Murray ME, Rabinovici GD.

Alzheimers Dement. 2019 Feb;15(2):205-216. doi: 10.1016/j.jalz.2018.09.001. Epub 2018 Oct 19.

PMID:
30347188
27.

Risk of Alzheimer's Disease in Obstructive Sleep Apnea Syndrome: Amyloid-β and Tau Imaging.

Elias A, Cummins T, Tyrrell R, Lamb F, Dore V, Williams R, Rosenfeld JV, Hopwood M, Villemagne VL, Rowe CC.

J Alzheimers Dis. 2018;66(2):733-741. doi: 10.3233/JAD-180640.

PMID:
30320587
28.

Superior Memory Reduces 8-year Risk of Mild Cognitive Impairment and Dementia But Not Amyloid β-Associated Cognitive Decline in Older Adults.

Dang C, Harrington KD, Lim YY, Ames D, Hassenstab J, Laws SM, Yassi N, Hickey M, Rainey-Smith SR, Robertson J, Rowe CC, Sohrabi HR, Salvado O, Weinborn M, Villemagne VL, Masters CL, Maruff P; AIBL Research Group.

Arch Clin Neuropsychol. 2018 Oct 1. doi: 10.1093/arclin/acy078. [Epub ahead of print]

PMID:
30272115
29.

Prevalence of amyloid-β pathology in distinct variants of primary progressive aphasia.

Bergeron D, Gorno-Tempini ML, Rabinovici GD, Santos-Santos MA, Seeley W, Miller BL, Pijnenburg Y, Keulen MA, Groot C, van Berckel BNM, van der Flier WM, Scheltens P, Rohrer JD, Warren JD, Schott JM, Fox NC, Sanchez-Valle R, Grau-Rivera O, Gelpi E, Seelaar H, Papma JM, van Swieten JC, Hodges JR, Leyton CE, Piguet O, Rogalski EJ, Mesulam MM, Koric L, Nora K, Pariente J, Dickerson B, Mackenzie IR, Hsiung GR, Belliard S, Irwin DJ, Wolk DA, Grossman M, Jones M, Harris J, Mann D, Snowden JS, Chrem-Mendez P, Calandri IL, Amengual AA, Miguet-Alfonsi C, Magnin E, Magnani G, Santangelo R, Deramecourt V, Pasquier F, Mattsson N, Nilsson C, Hansson O, Keith J, Masellis M, Black SE, Matías-Guiu JA, Cabrera-Martin MN, Paquet C, Dumurgier J, Teichmann M, Sarazin M, Bottlaender M, Dubois B, Rowe CC, Villemagne VL, Vandenberghe R, Granadillo E, Teng E, Mendez M, Meyer PT, Frings L, Lleó A, Blesa R, Fortea J, Seo SW, Diehl-Schmid J, Grimmer T, Frederiksen KS, Sánchez-Juan P, Chételat G, Jansen W, Bouchard RW, Laforce RJ, Visser PJ, Ossenkoppele R.

Ann Neurol. 2018 Nov;84(5):729-740. doi: 10.1002/ana.25333.

30.

Targeting metals rescues the phenotype in an animal model of tauopathy.

Sedjahtera A, Gunawan L, Bray L, Hung LW, Parsons J, Okamura N, Villemagne VL, Yanai K, Liu XM, Chan J, Bush AI, Finkelstein DI, Barnham KJ, Cherny RA, Adlard PA.

Metallomics. 2018 Sep 19;10(9):1339-1347. doi: 10.1039/c8mt00153g.

PMID:
30168573
31.

Relationship Between Amyloid-β Positivity and Progression to Mild Cognitive Impairment or Dementia over 8 Years in Cognitively Normal Older Adults.

Dang C, Harrington KD, Lim YY, Ames D, Hassenstab J, Laws SM, Yassi N, Hickey M, Rainey-Smith S, Robertson J, Sohrabi HR, Salvado O, Weinborn M, Villemagne VL, Rowe CC, Masters CL, Maruff P; AIBL Research Group.

J Alzheimers Dis. 2018;65(4):1313-1325. doi: 10.3233/JAD-180507.

PMID:
30149452
32.

Implementing the centiloid transformation for 11C-PiB and β-amyloid 18F-PET tracers using CapAIBL.

Bourgeat P, Doré V, Fripp J, Ames D, Masters CL, Salvado O, Villemagne VL, Rowe CC; AIBL research group.

Neuroimage. 2018 Dec;183:387-393. doi: 10.1016/j.neuroimage.2018.08.044. Epub 2018 Aug 18.

PMID:
30130643
33.

Episodic Memory and Learning Dysfunction Over an 18-Month Period in Preclinical and Prodromal Alzheimer's Disease.

Baker JE, Lim YY, Jaeger J, Ames D, Lautenschlager NT, Robertson J, Pietrzak RH, Snyder PJ, Villemagne VL, Rowe CC, Masters CL, Maruff P.

J Alzheimers Dis. 2018;65(3):977-988. doi: 10.3233/JAD-180344.

PMID:
30103330
34.

Estimates of age-related memory decline are inflated by unrecognized Alzheimer's disease.

Harrington KD, Schembri A, Lim YY, Dang C, Ames D, Hassenstab J, Laws SM, Rainey-Smith S, Robertson J, Rowe CC, Sohrabi HR, Salvado O, Weinborn M, Villemagne VL, Masters CL, Maruff P; AIBL Research Group.

Neurobiol Aging. 2018 Oct;70:170-179. doi: 10.1016/j.neurobiolaging.2018.06.005. Epub 2018 Jun 11.

PMID:
30015036
35.

Author Correction: Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions.

Villemagne VL, Doré V, Burnham SC, Masters CL, Rowe CC.

Nat Rev Neurol. 2018 Jul;14(7):446. doi: 10.1038/s41582-018-0021-z.

PMID:
29880829
36.

Sex, amyloid, and APOE ε4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well-characterized cohorts.

Buckley RF, Mormino EC, Amariglio RE, Properzi MJ, Rabin JS, Lim YY, Papp KV, Jacobs HIL, Burnham S, Hanseeuw BJ, Doré V, Dobson A, Masters CL, Waller M, Rowe CC, Maruff P, Donohue MC, Rentz DM, Kirn D, Hedden T, Chhatwal J, Schultz AP, Johnson KA, Villemagne VL, Sperling RA; Alzheimer's Disease Neuroimaging Initiative; Australian Imaging, Biomarker and Lifestyle study of ageing; Harvard Aging Brain Study.

Alzheimers Dement. 2018 Sep;14(9):1193-1203. doi: 10.1016/j.jalz.2018.04.010. Epub 2018 May 24.

37.

Neuropsychology and neuroimaging profiles of amyloid-positive versus amyloid-negative amnestic mild cognitive impairment patients.

Tomadesso C, de La Sayette V, de Flores R, Bourgeat P, Villemagne VL, Egret S, Eustache F, Chételat G.

Alzheimers Dement (Amst). 2018 Mar 17;10:269-277. doi: 10.1016/j.dadm.2018.02.008. eCollection 2018.

38.

Self-Reported Physical Activity is Associated with Tau Burden Measured by Positron Emission Tomography.

Brown BM, Rainey-Smith SR, Dore V, Peiffer JJ, Burnham SC, Laws SM, Taddei K, Ames D, Masters CL, Rowe CC, Martins RN, Villemagne VL.

J Alzheimers Dis. 2018;63(4):1299-1305. doi: 10.3233/JAD-170998.

PMID:
29758940
39.

Reply: Cortical tau pathology: a major player in fibre-specific white matter reductions in Alzheimer's disease?

Mito R, Raffelt D, Dhollander T, Vaughan DN, Tournier JD, Salvado O, Brodtmann A, Rowe CC, Villemagne VL, Connelly A.

Brain. 2018 Jun 1;141(6):e45. doi: 10.1093/brain/awy086. No abstract available.

PMID:
29668851
40.

Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease.

Mattsson N, Groot C, Jansen WJ, Landau SM, Villemagne VL, Engelborghs S, Mintun MM, Lleo A, Molinuevo JL, Jagust WJ, Frisoni GB, Ivanoiu A, Chételat G, Resende de Oliveira C, Rodrigue KM, Kornhuber J, Wallin A, Klimkowicz-Mrowiec A, Kandimalla R, Popp J, Aalten PP, Aarsland D, Alcolea D, Almdahl IS, Baldeiras I, van Buchem MA, Cavedo E, Chen K, Cohen AD, Förster S, Fortea J, Frederiksen KS, Freund-Levi Y, Gill KD, Gkatzima O, Grimmer T, Hampel H, Herukka SK, Johannsen P, van Laere K, de Leon MJ, Maier W, Marcusson J, Meulenbroek O, Møllergård HM, Morris JC, Mroczko B, Nordlund A, Prabhakar S, Peters O, Rami L, Rodríguez-Rodríguez E, Roe CM, Rüther E, Santana I, Schröder J, Seo SW, Soininen H, Spiru L, Stomrud E, Struyfs H, Teunissen CE, Verhey FRJ, Vos SJB, van Waalwijk van Doorn LJC, Waldemar G, Wallin ÅK, Wiltfang J, Vandenberghe R, Brooks DJ, Fladby T, Rowe CC, Drzezga A, Verbeek MM, Sarazin M, Wolk DA, Fleisher AS, Klunk WE, Na DL, Sánchez-Juan P, Lee DY, Nordberg A, Tsolaki M, Camus V, Rinne JO, Fagan AM, Zetterberg H, Blennow K, Rabinovici GD, Hansson O, van Berckel BNM, van der Flier WM, Scheltens P, Visser PJ, Ossenkoppele R.

Alzheimers Dement. 2018 Jul;14(7):913-924. doi: 10.1016/j.jalz.2018.02.009. Epub 2018 Mar 28.

PMID:
29601787
41.

Genetic variation in Aquaporin-4 moderates the relationship between sleep and brain Aβ-amyloid burden.

Rainey-Smith SR, Mazzucchelli GN, Villemagne VL, Brown BM, Porter T, Weinborn M, Bucks RS, Milicic L, Sohrabi HR, Taddei K, Ames D, Maruff P, Masters CL, Rowe CC, Salvado O, Martins RN, Laws SM; AIBL Research Group.

Transl Psychiatry. 2018 Feb 26;8(1):47. doi: 10.1038/s41398-018-0094-x.

42.

Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions.

Villemagne VL, Doré V, Burnham SC, Masters CL, Rowe CC.

Nat Rev Neurol. 2018 Apr;14(4):225-236. doi: 10.1038/nrneurol.2018.9. Epub 2018 Feb 16. Review. Erratum in: Nat Rev Neurol. 2018 Jul;14(7):446.

PMID:
29449700
43.

High performance plasma amyloid-β biomarkers for Alzheimer's disease.

Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Doré V, Fowler C, Li QX, Martins R, Rowe C, Tomita T, Matsuzaki K, Ishii K, Ishii K, Arahata Y, Iwamoto S, Ito K, Tanaka K, Masters CL, Yanagisawa K.

Nature. 2018 Feb 8;554(7691):249-254. doi: 10.1038/nature25456. Epub 2018 Jan 31.

PMID:
29420472
44.

KIBRA is associated with accelerated cognitive decline and hippocampal atrophy in APOE ε4-positive cognitively normal adults with high Aβ-amyloid burden.

Porter T, Burnham SC, Doré V, Savage G, Bourgeat P, Begemann K, Milicic L, Ames D, Bush AI, Maruff P, Masters CL, Rowe CC, Rainey-Smith S, Martins RN, Groth D, Verdile G, Villemagne VL, Laws SM.

Sci Rep. 2018 Feb 1;8(1):2034. doi: 10.1038/s41598-018-20513-y.

45.

Associations of Dietary Protein and Fiber Intake with Brain and Blood Amyloid-β.

Fernando WMADB, Rainey-Smith SR, Gardener SL, Villemagne VL, Burnham SC, Macaulay SL, Brown BM, Gupta VB, Sohrabi HR, Weinborn M, Taddei K, Laws SM, Goozee K, Ames D, Fowler C, Maruff P, Masters CL, Salvado O, Rowe CC, Martins RN; AIBL Research Group.

J Alzheimers Dis. 2018;61(4):1589-1598. doi: 10.3233/JAD-170742.

PMID:
29376865
46.

Association of β-Amyloid and Apolipoprotein E ε4 With Memory Decline in Preclinical Alzheimer Disease.

Lim YY, Kalinowski P, Pietrzak RH, Laws SM, Burnham SC, Ames D, Villemagne VL, Fowler CJ, Rainey-Smith SR, Martins RN, Rowe CC, Masters CL, Maruff PT.

JAMA Neurol. 2018 Apr 1;75(4):488-494. doi: 10.1001/jamaneurol.2017.4325.

47.

Amyloid burden and incident depressive symptoms in preclinical Alzheimer's disease.

Perin S, Harrington KD, Lim YY, Ellis K, Ames D, Pietrzak RH, Schembri A, Rainey-Smith S, Salvado O, Laws SM, Martins RN, Villemagne VL, Rowe CC, Masters CL, Maruff P; AIBL research group.

J Affect Disord. 2018 Mar 15;229:269-274. doi: 10.1016/j.jad.2017.12.101. Epub 2018 Jan 3.

PMID:
29329059
48.

Fibre-specific white matter reductions in Alzheimer's disease and mild cognitive impairment.

Mito R, Raffelt D, Dhollander T, Vaughan DN, Tournier JD, Salvado O, Brodtmann A, Rowe CC, Villemagne VL, Connelly A.

Brain. 2018 Mar 1;141(3):888-902. doi: 10.1093/brain/awx355.

PMID:
29309541
49.

Effect of Structural Modifications to Glyoxal-bis(thiosemicarbazonato)copper(II) Complexes on Cellular Copper Uptake, Copper-Mediated ATP7A Trafficking, and P-Glycoprotein Mediated Efflux.

Acevedo KM, Hayne DJ, McInnes LE, Noor A, Duncan C, Moujalled D, Volitakis I, Rigopoulos A, Barnham KJ, Villemagne VL, White AR, Donnelly PS.

J Med Chem. 2018 Feb 8;61(3):711-723. doi: 10.1021/acs.jmedchem.7b01158. Epub 2018 Jan 8.

PMID:
29232129
50.

A randomized, exploratory molecular imaging study targeting amyloid β with a novel 8-OH quinoline in Alzheimer's disease: The PBT2-204 IMAGINE study.

Villemagne VL, Rowe CC, Barnham KJ, Cherny R, Woodward M, Bozinosvski S, Salvado O, Bourgeat P, Perez K, Fowler C, Rembach A, Maruff P, Ritchie C, Tanzi R, Masters CL.

Alzheimers Dement (N Y). 2017 Nov 9;3(4):622-635. doi: 10.1016/j.trci.2017.10.001. eCollection 2017 Nov.

Supplemental Content

Loading ...
Support Center